Join Iolyx Therapeutics for a virtual key opinion leader (KOL) event featuring Dr. Penny Asbell (University of Memphis, Department of Biomedical Engineering), Dr. Mark Hinds (Ophthalmic Trials Australia), and Dr. Houman Hemmati (Consulting Medical Director at Iolyx Therapeutics, Co-Founder of Optigo Biotherapeutics), who will join company management to discuss the unmet need and current treatment landscape for dry eye disease (DED).

The event will focus on the significant unmet therapeutic need in DED, as well as data from Iolyx’s ILYX-002-201 Phase 2 clinical trial evaluating ILYX-002 in patients with moderate-to-severe DED associated with systemic autoimmune or inflammatory disorders. ILYX-002 is a broadly acting, potent, and specific immune-modulator acting on the Th17 and Th1 dysregulation commonly present in inflammatory ocular surface diseases. It is presented as a sterile, preservative-free ophthalmic suspension.

A live question and answer session will follow the formal presentations.